Kardiotoxizität nach Strahlentherapie beim Mammakarzinom – Mythen und Fakten

Die Strahlentherapie ist wichtiger Bestandteil in der multidisziplinären Behandlung des Mammakarzinoms. In den letzten Jahren wurde mehrfach über kardiale Risiken der Bestrahlung diskutiert. Dies Problem ist seit langem bekannt und aus strahlentherapeutischer Sicht gelöst. Die aktuelle Datenlage wird hier kurz dargestellt.

• Literatur

• 1 Cuzick J, Stewart H, Peto R et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. CancerTreat Rep 1987; 71: 15-29
• 2 Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106
• 3 Early Breast Cancer Trialists’ Collaborative Group. Darby S, McGale P et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 2011; 378: 1707-1716
• 4 Henson KE, McGale P, Taylor C et al. Radiation-related mortality from heart disease and lung cancer more than 20 yearsafter radiotherapy for breast cancer. Brit J Cancer 2013; 108: 179-182
• 5 Sautter-Bihl ML, Sedlmayer F, Budach W et al. DEGRO practical guidelines: radiotherapy of breast cancer III-radiotherapy of the lymphatic pathways. Strahlenther Onkol 2014; 190: 342-351
• 6 Darby SC, Ewertz M, McGale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-998
• 7 Applefield MM, Slawson RG, Spicer KM et al. Long-term cardiovascular evaluation of patients with Hodgkin´s disease treated by thoracic mantle radiation therapy. Cancer Treat Rep 1982; 66: 1003-1013
• 8 Mill WB, Baglan RJ, Kurichety P et al. Symptomatic radiation-induced pericarditis in Hodgkin´s disease. Int J Radiat Oncol Biol Phys 1984; 10: 2061-2065
• 9 Schultz-Hector S, Böhm M, Blöchel A et al. Radiation-induced heart disease: morphology, changes in catecholamine synthesis and content, beta-adrenoceptor density, and hemodynamic function in an experimental model. Radiat Res 1992; 129: 281-289
• 10 Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?. Int J Radiat Oncol Biol Phys 2007; 67: 10-18
• 11 Friedrich SA, Unverdorben M, Kunkel B et al. Kardiale Spätfolgen nach Mantelfeldbestrahlung. Strahlenther Onkol 1996; 172: 19-24
• 12 Taylor CW, Nisbet A, McGale P et al. Cardiac doses from Swedish breast cancer radiotherapy since the 1950 s. Radiother Oncol 2009; 90: 127-135
• 13 Dellas K, Zimmer K, Boicev A et al. Hypofractionation with simultaneous integrated boost for early breast cancer: Results of the German multicenter Phase II trial (ARO-2010–01). Strahlenther Onkol (im Druck)
• 14 Poortmans P, Struikmans H, Kirkove C et al. Irradiation of the internal mammary and medial supraclacvicular lymph node chain in stage I-III breast cancer: final analysis of all 4004 patients. ECCO 17. 2013 Abstract
• 15 Schaffer R, Tyldsley S, Rolles S et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 2009; 90: 122-126
• 16 Petersen C, Würschmidt F. Late Toxicity of Radiotherapy: A problem or a challenge for the radiation oncologist?. Breast Care (Basel) 2011; 6: 369-374
• 17 Schlitt A, Jordan K, Vordermark D et al. Cardiotoxicity and oncological treatment. Dt. Arztebl Int 2014; 111: 161-169
• 18 Pedersen AN, Korreman S, Nyström H et al. Breathing adapted radiotherapy of breast cancer: reduction of cardiac and pulmonary doses using voluntary inspiration breath hold. Radiother Oncol 2004; 72: 53-60
• 19 Hjelstuen MH, Mjaaland I, Vikström J et al. Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular- and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk. Acta Oncol 2012; 51: 333-344
• 20 Nissen HD, Appelt AL. Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. Radiother Oncol 2013; 106: 28-32